DXC · DXC Technology
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $17.10
Note written ·
Price against the kill line
13.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $17.10, on record since 11 November 2026. The shares are up 41.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $17.10, about 12% above the $15.27 close on 11 November 2026 and over the $16.38 52-week high, would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Technology
Quarter to 30 September 2026, filed 30 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 3,034
- Revenue, change on a year (%)
- −4.0
- Gross margin (%)
- 21.8
- Operating margin (%)
- 6.2
- Free cash flow, four quarters ($M)
- 1,030
- Net cash, cash less debt ($M)
- −1,460
- Price to earnings (×)
- 20.4
- Enterprise value to sales (×)
- 0.3
All filed numbers
What DXC Technology reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 3,034 | −4.0 | 21.8 | 6.2 |
| first filed | 2,999 | −5.1 | 20.4 | 5.0 |
| first filed | 3,130 | −1.2 | 23.1 | 7.6 |
| first filed | 3,194 | −1.0 | 23.8 | 8.2 |
| first filed | 3,161 | −2.5 | 24.6 | 8.0 |
| first filed | 3,159 | −2.4 | 24.4 | 6.8 |
| Pre-tax income ($M) | 54.0 |
| Net income ($M) four quarters: 112 | 24.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −9.6 |
| Operating cash flow ($M) | 1,288 |
| Capital spending ($M) | 258 |
| Free cash flow ($M) | 1,030 |
| Cash and short-term investments ($M) | 1,599 |
| Debt ($M) long-term debt and finance leases | 3,059 |
| Net cash, cash less debt ($M) | −1,460 |
| Deferred revenue ($M) −10.4% on a year | 1,135 |
| Backlog, orders not yet delivered ($M) −3.1% on a year | 15,800 |
| Receivables ($M) | 2,815 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 3,057 |
| Market value ($M) | 2,290 |
| Enterprise value, market value plus net debt ($M) | 3,750 |
| Enterprise value to sales (×) | 0.3 |
| Enterprise value to operating income (×) | 4.5 |
| Price to earnings (×) | 20.4 |
| Price to book value (×) | 0.7 |
| Free-cash-flow yield (%) | 45.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 16.9% of shares outstanding sold short, 5.5 days of average trading to cover, +2.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $500K | $38K |
The thesis
DXC Technology's shares are more likely to lag the S&P 500 over the next three months than to lead it. They closed at $15.27 on 11 November 2026, above every price target named in analyst actions since the 29 October 2026 results, while the insurance-unit sale that supports them remains unsigned. A definitive agreement and its price settle the case.
The price already reflects a sale near the $2.4 billion Reuters reported on 19 October 2026: the shares are up 36.3% over three months, from an $11.20 close on 13 August 2026. BMO's $14 target, set on 30 October 2026, is the highest of the four firms that raised targets after the results. Company news through 10 November 2026 covers an AI summit sponsorship and a security-services article, with no signed deal and no change to guidance.
The rating is Low because the operating trend points down. DXC cut fiscal 2027 revenue and earnings guidance on 29 October 2026 after quarterly bookings fell 10%, and guided the December quarter well below consensus.
Bullish and bearish views on DXC Technology Company
The bull case on DXC Technology Company (DXC), in brief: reported price tops the market value. The bear case: guidance came down across the board.
Bull case
- Reported price tops the market value. Reuters reported on 19 October 2026 that Eldridge Industries was in advanced talks to buy the insurance unit for about $2.4 billion. MarketBeat listed DXC's market value at $2.27 billion on 3 November 2026. Market value excludes DXC's debt, and MarketBeat listed a debt-to-equity ratio of 0.90, so the sale price would not pass dollar for dollar to the shares.
- The company confirmed sale talks. DXC's 29 October 2026 results said it is in "ongoing discussions" about a possible sale of its insurance business. Reuters' sources said an agreement could come within weeks, while CEO Raul Fernandez gave no timing or terms on the 29 October 2026 call.
- The insurance unit is the growing part. Insurance Software & Services revenue rose 23.1% to $394 million in the September quarter, with an 11.4% segment margin and bookings up 43.5%, according to DXC's 29 October 2026 release. That revenue includes a one-time favorable contract modification.
- Cash generation held for the half. First-half free cash flow was $405 million, against $337 million a year earlier, and DXC kept its full-year outlook at about $600 million on 29 October 2026. The company repurchased $60 million of shares in the quarter, retiring about 5.7 million.
Bear case
- Guidance came down across the board. DXC cut fiscal 2027 revenue guidance from $12.10–$12.35 billion to $11.91–$11.98 billion on 29 October 2026. It cut adjusted earnings guidance from $2.40–$2.90 to $2.25–$2.50 per share, against a $2.59 consensus, Benzinga reported. Organic revenue is now expected to fall 5.0%–5.5%.
- Bookings point to more decline. September-quarter bookings fell 10% to $2.4 billion, a book-to-bill ratio of 0.80x, meaning new contracts covered 80% of revenue billed. Consulting & Engineering Services bookings fell 17.0% and Global Infrastructure Services bookings fell 12.7%, according to the 29 October 2026 release.
- Revenue keeps shrinking. The 10-Q filed on 30 October 2026 shows quarterly revenue of $3.03 billion for the period ended 30 September 2026, against $3.16 billion a year earlier.
- Next quarter is guided below consensus. DXC guided fiscal third-quarter revenue to about $2.98 billion and adjusted earnings to about $0.55 per share. Consensus had been $3.081 billion and $0.80, Benzinga reported on 29 October 2026.
- The quarter's beat had help. Revenue of $3.034 billion and adjusted earnings of $0.67 per share topped the $2.996 billion and $0.55 consensus, Benzinga reported on 29 October 2026. Management said a one-time insurance contract modification helped.
- Targets rose but trail the shares. Morgan Stanley raised its target to $12 from $9 on 2 November 2026; on 30 October 2026 JPMorgan went to $13 from $12, Susquehanna to $12 from $10 and BMO to $14 from $11. Walnut's tracker shows a $12.50 average, and MarketBeat listed a $12.06 consensus with seven hold and three sell ratings on 3 November 2026.
- A sale removes the growing unit. The insurance segment brought in about $1.28 billion of revenue in fiscal 2026, roughly 10% of DXC's total, Benzinga reported. The company that remains would rely on segments with falling bookings.
Price setup
The last close was $15.27 on 11 November 2026, 6.8% below the 52-week intraday high of $16.38 set on 26 October 2026. The 52-week closing low was $8.22 on 13 May 2026. Closes between 4 November 2026 and 11 November 2026 held in a narrow range from $14.86 to $15.31.
As of the 11 November 2026 close, the 50-day moving average was $12.92 and the 200-day was $11.56. The shares sit about 18% above the 50-day average and above BMO's $14 target, the highest of the post-results targets. A return toward $12.92 would erase most of the gain that followed the 19 October 2026 Reuters report.
SEC Form 4 filings from August and September 2026 show stock awards to two presidents and shares withheld for tax at $10.79 on 14 August 2026, with no open-market purchases or sales by insiders. No earnings report falls in the next 30 days: Walnut estimates the next one around 28 January 2027.
Catalysts ahead
- ~December 2026 (est.): Possible definitive agreement to sell the insurance unit, reported by Reuters as being negotiated with Eldridge Industries. A signed deal near $2.4 billion would confirm the main support left after the guidance cut. Talks ending would remove it.
- ~28 January 2027 (est.): Fiscal third-quarter 2027 results. Shows whether bookings recover from the 0.80x book-to-bill and whether revenue meets the roughly $2.98 billion guide.
What would change the view
A daily close above $17.10, about 12% above the $15.27 close on 11 November 2026 and over the $16.38 52-week high, would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
The largest recent moves came from company events: the 19 October 2026 sale report, which GuruFocus said lifted the shares about 10%, and the 29 October 2026 results. MarketBeat listed a beta of 0.79 on 3 November 2026. The next large move is more likely to follow deal news than the S&P 500. A sustained drop alongside other IT-services shares with no change in deal news would show that sector moves matter more than this view assumes.
The evidence, claim by claim (8)
- Fiscal second-quarter 2027 revenue was $3.034 billion, down 4.0% reported and organically. Non-GAAP diluted EPS was $0.67, down 20.2%, against a $0.55 consensus. DXC fiscal Q2 2027 results release; Benzinga 29 October 2026 · as of
- Quarterly bookings fell 10% to $2.4 billion, a 0.80x book-to-bill. Consulting & Engineering Services bookings fell 17.0% and Global Infrastructure Services bookings fell 12.7%. DXC fiscal Q2 2027 results release · as of
- DXC cut fiscal 2027 revenue guidance to $11.91–$11.98 billion from $12.10–$12.35 billion, and non-GAAP EPS guidance to $2.25–$2.50 from $2.40–$2.90. Free cash flow guidance stayed at about $600 million. DXC fiscal Q2 2027 results release; Benzinga 29 October 2026 · as of
- DXC guided fiscal Q3 2027 revenue to about $2.98 billion and non-GAAP EPS to about $0.55, against consensus of $3.081 billion and $0.80. Benzinga, 29 October 2026 · as of
- Insurance Software & Services revenue rose 23.1% to $394 million, including a favorable contract modification. Segment margin was 11.4%, and bookings rose 43.5%. DXC fiscal Q2 2027 results release · as of
- Reuters reported DXC is in advanced talks to sell its insurance software and services unit to Eldridge Industries for about $2.4 billion, citing sources who said a deal is not certain. Reuters, 19 October 2026 · as of
- BMO raised its target to $14 from $11, JPMorgan to $13 from $12 and Susquehanna to $12 from $10 on 30 October 2026; Morgan Stanley raised its target to $12 from $9 on 2 November 2026. Benzinga analyst action reports, 30 October 2026 and 2 November 2026 · as of
- Quarterly revenue for the period ended 30 September 2026 was $3.03 billion, against $3.16 billion in the same quarter a year earlier. DXC Form 10-Q filed 30 October 2026 · as of
Sources
- Exclusive-DXC in advanced talks to sell insurance software unit for $2.4 billion, sources say · 933thedrive.com ·
- Why Is DXC Technology Stock Gaining Monday? · benzinga.com
- DXC Technology (NYSE:DXC) Shares Down 6.3% - Should You Sell? · marketbeat.com ·
- DXC Technology (NYSE:DXC) Stock Price Expected to Rise, Morgan Stanley Analyst Says · marketbeat.com ·
- DXC Technology (DXC) Stock Forecast and Price Target (2026) · walnutinvest.com
- DXC Technology Nears $2.4B Insurance Unit Sale, Shares Jump 10% (DXC) · gurufocus.com
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…